How to Get Wegovy Covered

Insurance Coverage for Wegovy: Why It Is So Hard and What You Can Do

Getting insurance to pay for Wegovy is one of the most frustrating parts of starting a GLP-1 weight loss medication. Dr. Alicia Shelly, a board-certified internist, walks through the process in this video, and her perspective is valuable because she sees both sides: the clinical need for these medications and the bureaucratic wall that insurance companies put up. If you have ever had a prior authorization denied or been told your plan does not cover weight loss drugs, this video speaks directly to that experience. Dr. Shelly breaks down the steps you can take to improve your chances of getting Wegovy approved by your insurer, from documentation strategies to appeal processes to alternative pathways when the insurance route fails completely.

The reality is that most private insurance plans and nearly all Medicare Part D plans either exclude weight loss medications entirely or make coverage so difficult to obtain that most patients give up. This is not because the medications do not work. Semaglutide has some of the strongest clinical evidence of any weight loss treatment ever developed. The exclusions exist because insurers are trying to limit their financial exposure. Each patient on Wegovy costs the plan roughly $15,000 per year, and with tens of millions of Americans who could qualify, the math scares insurance executives. Understanding this dynamic helps you approach the coverage fight more strategically. When you know why the system says no, you can build a stronger case for why it should say yes.

There is also a historical dimension to this problem that is worth understanding. Weight loss has traditionally been classified as a lifestyle concern rather than a medical one. This distinction is baked into insurance policy language that was written decades ago, before the science of obesity as a chronic disease was well-established. The American Medical Association officially recognized obesity as a disease in 2013, but insurance formularies have been slow to catch up. When your insurer denies Wegovy, they are operating under a framework that treats weight loss medication like cosmetic surgery rather than like blood pressure medication. Changing that framework is a fight happening at the legislative and regulatory level, but individual patients are caught in the middle of that transition.

The Prior Authorization Playbook

Dr. Shelly outlines what she calls the prior authorization playbook: the set of documentation and clinical arguments most likely to get a Wegovy prescription approved. The foundation is a well-documented medical history showing that obesity is a chronic condition affecting your health, more than a cosmetic concern. This means your doctor needs to include your BMI history over time, any obesity-related comorbidities like type 2 diabetes, hypertension, sleep apnea, osteoarthritis, or non-alcoholic fatty liver disease, and evidence that you have tried other weight loss methods without lasting success. The more clinical documentation your doctor can provide, the harder it is for the insurer to justify a denial.

The specific documentation matters more than you might think. A prior authorization that says "patient is obese and wants to lose weight" will almost certainly be denied. One that says "patient has a BMI of 38 with documented type 2 diabetes, stage 2 hypertension, moderate obstructive sleep apnea requiring CPAP, and has participated in structured weight loss programs in 2022 and 2024 without sustained results" tells a completely different story. The second version demonstrates medical necessity in language that insurance reviewers are trained to recognize. Dr. Shelly recommends that patients work with their doctor's office to ensure the prior authorization paperwork is thorough, specific, and clinically detailed rather than vague and brief.

She also discusses the appeal process, which is where many patients give up too early. A first-level denial is not the end of the road. Most states require insurers to allow at least one level of internal appeal, and many allow external review by an independent medical reviewer who is not employed by the insurance company. Dr. Shelly recommends that patients work closely with their doctor's office to write a detailed appeal letter that cites clinical guidelines from organizations like the American Association of Clinical Endocrinology, published research on semaglutide efficacy from the STEP clinical trial program, and the specific ways obesity is affecting your health outcomes. The key insight is that appeals are essentially legal documents, and they need to be treated with that level of seriousness, detail, and specificity.

One underappreciated tactic Dr. Shelly mentions is peer-to-peer review. When a prior authorization is denied, the prescribing doctor can request a conversation with the insurance company's medical director. This is a phone call between two physicians where your doctor makes the clinical case directly. Peer-to-peer reviews have a higher overturn rate than paper appeals because the conversation allows for real-time clinical discussion rather than form-letter responses. Not every doctor is willing to invest the time in a peer-to-peer call, so it is worth asking your provider whether they are willing to do this before you choose a practice.

What the Video Gets Right

Dr. Shelly is honest about the difficulty of the process without being discouraging. She accurately describes the prior authorization space and gives actionable advice rather than vague suggestions. Her recommendation to document everything and treat the appeal process as a formal clinical argument is spot-on. She also correctly notes that getting an Ozempic prescription for diabetes is sometimes easier than getting a Wegovy prescription for weight loss, even though they contain the same active ingredient, because insurers treat the two indications very differently. The video also does a good job of setting realistic expectations: even with perfect documentation, some insurers will still deny coverage, and patients need to be prepared for that outcome.

What the Video Misses

The video could benefit from more discussion of what to do when all insurance avenues fail. Many patients exhaust the appeal process and still get denied. At that point, options include manufacturer patient assistance programs, which can provide the drug at reduced or no cost for patients who meet income requirements. Compounding pharmacies offer semaglutide at dramatically lower prices, though the compounded versions are not identical to the brand-name product. Cash-pay discount programs like those offered through Costco or telehealth platforms can cut costs significantly. In some cases, switching to a different GLP-1 that may have better coverage on your specific plan is the most practical solution. The video also does not address employer self-funded plans, which operate under different rules than fully insured plans and may have more flexibility in adding GLP-1 coverage, particularly if the employer can be convinced that the drug reduces long-term healthcare costs.

There is also no discussion of the state-by-state variation in insurance laws and mandates. Some states have passed or are considering legislation that would require insurers to cover anti-obesity medications. If you live in one of these states, the rules may be different and more favorable than what Dr. Shelly describes. Knowing your state's insurance mandate space is another tool in the coverage toolkit that the video does not mention.

Questions to Bring to Your Doctor

Before your next appointment, think about these questions. Ask your doctor whether they have a dedicated staff member or process for handling prior authorizations for GLP-1 drugs. Some practices are much better at this than others, and the quality of the prior authorization paperwork makes a big difference in approval rates. Ask whether your specific plan has been known to approve or deny Wegovy, since your doctor's office may have experience with your insurer and can predict the likely outcome. Ask about alternative medications that might have better coverage on your plan, since tirzepatide, liraglutide, or other GLP-1 drugs may be on your formulary even when semaglutide is not. Ask about the peer-to-peer review option and whether your doctor is willing to do one if the first authorization is denied. Finally, ask your doctor to document all obesity-related health conditions in your chart at every visit, even if those conditions feel minor, because that documentation builds the case for medical necessity over time and strengthens future prior authorization attempts.

Who Should Watch This

This video is most relevant for people who have a doctor willing to prescribe Wegovy but are stuck on the insurance side. If you are early in the process and have not yet submitted a prior authorization, watching this first will help you prepare and avoid common mistakes that lead to denials. If you have already been denied, the appeal strategies discussed here are worth reviewing before you give up. The video is less useful for people on Medicare, since Medicare Part D currently excludes anti-obesity medications by law, though that policy may change in coming years depending on legislative action. It is also less relevant if you have already decided to go the cash-pay or compounding route, since the entire video focuses on navigating the insurance system.

The bottom line is that getting Wegovy covered requires persistence, documentation, and a willingness to fight through a system that is designed to say no. Dr. Shelly does a good job of showing you what that fight looks like and giving you the tools to push through it. The patients who get coverage are often the ones who refuse to accept the first denial and are willing to invest time in building a strong clinical case with their doctor. It is frustrating that this level of effort is required for a medication that clinical evidence strongly supports, but that is the current reality of the insurance space for weight loss drugs.